Results 11 to 20 of about 325,639 (307)
BPTF promotes tumor growth and predicts poor prognosis in lung adenocarcinomas. [PDF]
, 2015 BPTF, a subunit of NURF, is well known to be involved in the development of eukaryotic cell, but little is known about its roles in cancers, especially in non-small-cell lung cancer (NSCLC).
Dai, Meng +14 more
core +8 more sources
Lung Cancer Management, 2016 In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigations is the tumor tissue retrieval via biopsy at diagnosis and after occurrence of resistance.
Trombetta, D. +3 more
openaire +2 more sources
Frontiers in Oncology, 2012 The phosphatidylinositol 3-kinases (PI3Ks) are members of a family of intracellular lipid kinases that phosphorylate the 3'-hydroxyl group of phosphatidylinositol and phosphoinositides. PI3K regulate signaling pathways for neoplasia, including cell proliferation, adhesion, survival, and motility.
Martinez-Martí, Alex, Felip, Enriqueta
openaire +3 more sources
Gli1 mediates lung cancer cell proliferation and sonic hedgehog-dependent mesenchymal cell activation. [PDF]
, 2013 Non-Small-Cell-Lung-Cancer (NSCLC) represents approximately 85% of all lung cancers and remains poorly understood. While signaling pathways operative during organ development, including Sonic Hedgehog (Shh) and associated Gli transcription factors (Gli1 ...
Bermudez, Olga +4 more
core +3 more sources
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. [PDF]
, 2015 BackgroundKey effector(s) of mutated KRAS in lung cancer progression and metastasis are unknown. Here we investigated the role of PAK1/Crk axis in transduction of the oncogenic KRAS signal in non-small cell lung cancer (NSCLC).MethodsWe used NSCLC ...
Aljilani, Amir +7 more
core +2 more sources
Preoperative CYFRA 21-1 and CEA as Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer [PDF]
, 2008 Objective: To validate the prognostic value of preoperative levels of CYFRA 21-1, CEA and the corresponding tumor marker index (TMI) in patients with stage I non-small cell lung cancer (NSCLC). Methods: Two hundred forty stage I NSCLC patients (80 in pT1
Ankerst, Donna Pauler +7 more
core +1 more source
TTF-1/p63-positive poorly differentiated NSCLC: A histogenetic hypothesis from the basal reserve cell of the terminal respiratory unit [PDF]
, 2020 TTF-1 is expressed in the alveolar epithelium and in the basal cells of distal terminal bronchioles. It is considered the most sensitive and specific marker to define the adenocarcinoma arising from the terminal respiratory unit (TRU). TTF-1, CK7, CK5/6,
Barraco N. +8 more
core +1 more source
Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]
, 2016 Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios +4 more
core +3 more sources
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone [PDF]
, 2020 Alterations in the NRF2/KEAP1 pathway result in the constitutive activation of NRF2, leading to the aberrant induction of antioxidant and detoxification enzymes, including NQO1.
Boothman, David A. +6 more
core +1 more source
The efficacy of durvalumab in locally advanced lung carcinoma [PDF]
Archive of OncologyBackground: The integration of durvalumab, an immune checkpoint inhibitor, as consolidation therapy following platinum-based chemoradiotherapy has redefined the standard of care for patients with stage III, unresectable non-small cell lung cancer (NSCLC)
Knežević Isidora +3 more
doaj +1 more source